{"id":671368,"date":"2023-10-09T15:48:01","date_gmt":"2023-10-09T15:48:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=671368"},"modified":"2023-10-09T15:48:01","modified_gmt":"2023-10-09T15:48:01","slug":"follicular-lymphoma-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-market-companies-epizyme-xynomic-pharmaceuticals-mei-pharma-novartis-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/follicular-lymphoma-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-market-companies-epizyme-xynomic-pharmaceuticals-mei-pharma-novartis-pharmaceuticals_671368.html","title":{"rendered":"Follicular Lymphoma Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Market | Companies &#8211; Epizyme, Xynomic Pharmaceuticals, MEI Pharma, Novartis Pharmaceuticals"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1696842233.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Follicular Lymphoma Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Market | Companies - Epizyme, Xynomic Pharmaceuticals, MEI Pharma, Novartis Pharmaceuticals\" src=\"https:\/\/www.abnewswire.com\/uploads\/1696842233.jpeg\" alt=\"Follicular Lymphoma Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Market | Companies - Epizyme, Xynomic Pharmaceuticals, MEI Pharma, Novartis Pharmaceuticals\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Follicular Lymphoma Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Follicular Lymphoma, historical and forecasted epidemiology as well as the Follicular Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\"><strong>DelveInsight has launched a new report on&nbsp;&#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/follicular-lymphoma-market-insights?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">Follicular Lymphoma &#8211; Market Insights, Epidemiology, and Market Forecast-2032<\/a>&rdquo;.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Follicular Lymphoma Market Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>As per the study conducted by Green et al. (2017), titled &ldquo;Chromatin modifying gene mutations in follicular lymphoma,&rdquo; mutation frequency of KMT2D, CREBBP, EZH2, EP300, KMT2C, HIST1H1E, ARID1A, and SMARCA4 mutation was 72%, 65%, 25%, 15%, 13%, 14%, 11%, and 1%, respectively.<\/li>\n<li>As per the study conducted by Smith et al. (2015), titled &ldquo;Lymphoma incidence, survival, and prevalence 2004&ndash;2014: sub-type analyses from the UK&rsquo;s Hematological Malignancy Research Network,&rdquo; the incidence of FL was 3.23\/100,000.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Key benefits of the report:<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Follicular Lymphoma market report covers a descriptive overview and comprehensive insight of the Follicular Lymphoma Epidemiology and Follicular Lymphoma&nbsp; market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>The Follicular Lymphoma market report provides insights on the current and emerging therapies.<\/li>\n<li>Follicular Lymphoma market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n<li>The Follicular Lymphoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Follicular Lymphoma market.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>Download a sample report @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/follicular-lymphoma-market-insights?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/follicular-lymphoma-market-insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Follicular Lymphoma Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Follicular lymphoma is generally an indolent B cell lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma (FL) is characterized by diffuse lymphadenopathy, bone marrow involvement, splenomegaly, and less commonly other extranodal sites of involvement.<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/follicular-lymphoma-market-insights?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">Follicular Lymphoma Market<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The dynamics of the<strong>&nbsp;Follicular Lymphoma market&nbsp;<\/strong>are&nbsp;anticipated to change in the coming years owing to the expected launch of emerging therapies by companies such as Epizyme, Xynomic Pharmaceuticals, MEI Pharma, Novartis Pharmaceuticals, Innovent Biologics, and others during the study period 2019-2032.<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/follicular-lymphoma-market-insights?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Follicular Lymphoma Emerging Therapy Assessment<\/strong><\/a><\/p>\n<ul style=\"text-align: justify;\">\n<li>Tazverik (Tazemetostat): Epizyme<\/li>\n<li>Abexinostat: Xynomic Pharmaceuticals<\/li>\n<li>ME-401: MEI Pharma<\/li>\n<li>Tisagenlec leucel: Novartis Pharmaceuticals<\/li>\n<li>Parsaclisib (IBI376): Innovent Biologics<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis<\/p>\n<p style=\"text-align: justify;\">4. Follicular Lymphoma Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Follicular Lymphoma Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Follicular Lymphoma Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Follicular Lymphoma Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Follicular Lymphoma&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Follicular Lymphoma Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Follicular Lymphoma Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Follicular Lymphoma Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Follicular Lymphoma Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Market drivers<\/p>\n<p style=\"text-align: justify;\">16. Market barriers<\/p>\n<p style=\"text-align: justify;\">17. Appendix<\/p>\n<p style=\"text-align: justify;\">18. Follicular Lymphoma Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a free sample page report @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/follicular-lymphoma-market-insights?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/follicular-lymphoma-market-insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Follicular Lymphoma Pipeline<\/strong><\/p>\n<p style=\"text-align: justify;\">&#8220;Follicular Lymphoma Pipeline Insight, 2023&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Follicular Lymphoma market. A detailed picture of the Follicular Lymphoma pipeline landscape is provided, which includes the disease overview and Follicular Lymphoma treatment guidelines.<\/p>\n<p style=\"text-align: justify;\"><strong>Follicular Lymphoma Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8216;Follicular Lymphoma Epidemiology Forecast to 2032&#8217; report delivers an in-depth understanding of the disease, historical and forecasted Follicular Lymphoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=follicular-lymphoma-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-market-companies-epizyme-xynomic-pharmaceuticals-mei-pharma-novartis-pharmaceuticals\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +91-9650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=follicular-lymphoma-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-market-companies-epizyme-xynomic-pharmaceuticals-mei-pharma-novartis-pharmaceuticals\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Follicular Lymphoma Market DelveInsight&#8217;s &#8220;Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Follicular Lymphoma, historical and forecasted epidemiology as well as the Follicular Lymphoma market trends in the United States, EU5 (Germany, Spain, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/follicular-lymphoma-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-market-companies-epizyme-xynomic-pharmaceuticals-mei-pharma-novartis-pharmaceuticals_671368.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-671368","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/671368","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=671368"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/671368\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=671368"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=671368"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=671368"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}